Skip to the content
 

Publications

 
  • Silagy CA, McNeil JJ, Bulpitt CJ, Donnan GA, Tonkin AM, Worsam B. Rationale for a primary prevention study using low-dose aspirin to prevent coronary and cerebrovascular disease in the elderly. J Am Geriatr Soc 1991;39(5):484-91.
  • Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K. The PACE pilot study: 12-month results and implications for future primary prevention trials in the elderly. (Prevention with low-dose Aspirin of Cardiovascular disease in the Elderly). J Am Geriatr Soc 1994;42(6):643-7.
  • Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K. Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol & Therap 1993;54(1):84-89.
  • Nelson M, Reid C, Beilin L, Donnan G, Johnston C, Krum H, et al. Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE). Drugs Aging 2003;20(12):897-903.
  • Nelson MR, Liew D, Bertram M, Vos T. Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70. Brit Med J 2005;330(7503):1306.
  • Nelson MR, Reid CM, Ames DA, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Krum H, Storey S, Tonkin A, Wolfe R, Woods RL, McNeil JJ, Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. Medical Journal of Australia 2008;189(2):105-109